CAR-T CELL THERAPY

Poster number

Title

Submitting author

City and Country

265

Cardiovascular Events Among Adult Patients with Aggressive B-Cell Lymphoma Treated with Standard of Care Axicabtagene Ciloleucel and Tisagenlecleucel

Raphael Steiner

Houston, TX, USA

266

Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel (Tisa-cel) Infusion in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/r FL)

Nathan Fowler

Houston, TX, USA

267

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma: Updated analysis of the phase 1b PORTIA study

Ulrich Jaeger

Vienna, Austria

268

Relapse characterization in diffuse large B cell lymphoma patients undergoing commercial CAR-T cell therapy: experience from a single centre

Mariana Bastos-Oreiro

Madrid, Spain

269

A single-arm, open-label, pilot trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-lymphoblastic leukemia/lymphoma

Mingzhi Zhang

Zhengzhou, China

270

Patients with out of specification Tisagenlecleucel can be salvaged with a point-of-care CAR T-cells: An observational intention-to-treat single-center analysis

Shalev Fried

Tel Hashomer, Israel

271

Extranodal Disease Is Associated with Shorter Progression-free Survival after CD19-CAR T-cell Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Veit Bücklein

Munich, Germany

272

Comparative efficacy of Tisagenlecleucel (tisa-cel) and Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory Diffuse Large B-cell Lymphoma (r/r DLBCL)

Richard Maziarz

Portland, OR, USA

273

OUTREACH: Preliminary Safety & Efficacy Results From a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting

John Godwin

Portland, OR, USA

274

Outcome determinants of commercial CAR-T cell therapy for large B-cell lymphoma: results of the GLA/DRST Real World Analysis

Peter Dreger

Muenster, Germany

275

FIRST REPORT OF THE REAL-LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR-T CELL IN DIFFUSE LARGE B-CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY

Annalisa Chiappella

Milano, Italy

276

FDG-PET imaging and radiomics in response assessment of lymphoma patients undergoing CAR T-cell therapy

Beatrice Casadei

Bologna, Italy

277

QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS TREATED WITH ANTI-CD19 CAR T-CELLS

Anna Dodero

Milano, Italy

278

Resistance of B-cell lymphomas to CAR-T cell therapy is associated with histophenotypical and genomic tumor changes which can induce profound trans-differentiation

Camille Laurent

Toulouse, France

279

In vitro analysis predicts clinical response of B cell lymphatic malignancies to CD19 CAR-T cells: phenotypic, transcriptional and functional study

Katia Beider

Ramat Gan, Israel